KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Accumulated Expenses (2016 - 2026)

Pacific Biosciences Of California has reported Accumulated Expenses over the past 15 years, most recently at $33.6 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 48.91% year-over-year to $33.6 million; the TTM value through Dec 2025 reached $33.6 million, up 48.91%, while the annual FY2025 figure was $33.6 million, 48.91% up from the prior year.
  • Accumulated Expenses for Q4 2025 was $33.6 million at Pacific Biosciences Of California, up from $29.2 million in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $45.7 million in Q4 2023 and troughed at $14.7 million in Q1 2021.
  • A 5-year average of $26.7 million and a median of $25.2 million in 2022 define the central range for Accumulated Expenses.
  • Biggest five-year swings in Accumulated Expenses: skyrocketed 109.0% in 2021 and later tumbled 50.57% in 2024.
  • Year by year, Accumulated Expenses stood at $36.3 million in 2021, then dropped by 10.11% to $32.6 million in 2022, then surged by 40.23% to $45.7 million in 2023, then tumbled by 50.57% to $22.6 million in 2024, then surged by 48.91% to $33.6 million in 2025.
  • Business Quant data shows Accumulated Expenses for PACB at $33.6 million in Q4 2025, $29.2 million in Q3 2025, and $26.5 million in Q2 2025.